January 13–15, 2025 | San Francisco, CA,
January 21–22, 2025 | Virtual
Biotech Showcase: An all-inclusive healthcare conference
Now in it's seventeenth annual edition, Biotech Showcase is your premier access to the life science ecosystem
About Biotech Showcase
Biotech Showcase, along with its family of events, Seed Showcase and TechBio Showcase, is a dedicated investor conference designed to provide private and micro-mid-cap biotechnology companies with the opportunity to present to and connect with investors and biopharmaceutical executives. With a roster of over 400 carefully selected presenting companies from across the globe, ranging from seed-stage startups to established multinational corporations, encompassing diverse fields such as platform technologies, therapeutic areas, digital health, devices, and diagnostics, these events attract investors wielding over USD 400 billion in capital and motivated strategic partners within the life science ecosystem.
For the upcoming edition, Biotech Showcase will embrace a hybrid format. In-person activities will unfold from January 8–10, 2024, at the Hilton San Francisco Union Square in San Francisco, California. Following this, the virtual components will take place during the subsequent week, from January 16–17, 2024, hosted on the partneringONE platform—an all-in-one digital experience that seamlessly combines both aspects of the event.
Specialized Tracks
Seed Showcase
Where transformational funding brings biotech innovation to the world stage
TechBio Showcase
Reimagining the role of technology in biology and human health.
Remarkable growth experienced
The number of attendees has shown a steady upward trend, starting at 732 in 2010 and rising to 3,224 in 2023, confirming a consistent increase in participation over the years.
The number of one-on-one meetings has also surged dramatically. From 550 meetings in 2010, the number skyrocketed to 7,809 in 2023, demonstrating the event's increasing effectiveness in fostering connections.
Attendee profile
Biotech Showcase welcomes a diverse spectrum of companies, spanning from seed-stage startups to small- and mid-cap private and public biotech and pharmaceutical firms at various stages of development.